Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HELIX BIOPHARMA (HBP:TSE) -- Ignore unavailable to you. Want to Upgrade?

To: Dick Martin who wrote (183)	3/29/1999 4:16:00 PM
From: burner	Respond to of 193

Helix Biopharma Corp - Helix increases six-month revenue Helix Biopharma Corp HBP Shares issued 13,776,415 1999-03-26 close $0.65 Monday Mar 29 1999 An anonymous director reports For the six months ended Jan. 31, 1999, revenues increased nearly 24 per cent over the same period in 1998 due to increased royalties from product and service licencing agreements. Expenses are down by nearly $1-million, more than 40 per cent lower than 1998. Research and development costs are lower in the second quarter due to the effects of renegotiating collaboration agreements with the company's academic and research partners. Helix has received a commitment of approximately $1.7-million from the Protein Engineering Network of Centers of Excellence to match Helix's expenditures toward the development of Helix's molecular sensor technology. At the end of the second quarter, the company had $793,891 in cash and treasury bills and a commitment from investors in a subsidiary company, Sensium Technologies Inc., for a cash investment of $925,000. Helix continues to collect its note receivable in monthly instalments from Lifecodes Corporation from the sale of the DNA identity testing business. CONSOLIDATED INCOME STATEMENT Six months ended Jan. 31 1999 1998 Revenue $ 828,354 $ 669,292 ----------- ----------- Expenses (excluding research and development) 892,014 1,648,883 Research and development 421,941 639,878 ----------- ----------- (485,600) (1,619,470) Earnings from discontinued operations - 90,625 ----------- ----------- (Loss) before income taxes (485,600) (1,528,845) Income taxes 20,367 - ----------- ----------- Net (loss) $ (505,967) $(1,528,845) =========== =========== Loss per share From continuing operations (4 cents) (12 cents) After discontinued operations (4 cents) (11 cents)

To: Dick Martin who wrote (183)	4/23/1999 10:35:00 PM
From: burner	Read Replies (1) \| Respond to of 193

Helix Biopharma Corp - Helix says insulin has been delivered through skin without injection Helix Biopharma Corp HBP Shares issued 13,776,415 1999-04-22 close $0.85 Friday Apr 23 1999 Dr. Richard Rossman reports Insulin has been successfully delivered in sustained quantities in animal experiments using a BIPHASIX skin patch and without the need for any injections. Diabetic rats were shown to have significantly reduced blood glucose levels following their treatment with porcine insulin using the injectionless BIPHASIX delivery system in a skin patch. Blood glucose levels in the treated animals remained reduced for more than 30 hours. As a result of this significant development, Helix BioPharma has decided to begin developing human insulin formulations with the ultimate aim of producing an insulin patch as a means of reducing the need for injections and improving patient compliance. The company's BIPHASIX uses a unique, lipid-based, microencapsulation process, which is capable of delivering a wide variety of pharmaceuticals of varying size, weight and solubilities. This technology is particularly well suited to biologically derived pharmaceuticals including DNA and proteins such as insulin and interferon. Great news IMO. This one has been threatening a breakout and maybe this news will do it. Be great to get a major pharmaceutical co involved Dan